Published in Clin Transl Sci on December 01, 2009
Designing drug trials: considerations for pregnant women. Clin Infect Dis (2014) 0.85
Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn (2016) 0.78
Clinical trials during pregnancy: what has been done. Eur J Clin Pharmacol (2011) 0.76
Pharmacogenetics and individualizing drug treatment during pregnancy. Pharmacogenomics (2014) 0.75
Brief interventions for alcohol problems: a review. Addiction (1993) 8.64
Birth outcomes in pregnant women taking fluoxetine. N Engl J Med (1996) 5.38
The prevalence of illicit-drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida. N Engl J Med (1990) 5.16
Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry (2009) 3.94
The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol (2009) 3.52
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2003) 3.34
The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev (1997) 2.96
Neurobiology of addiction. Curr Opin Neurobiol (1996) 2.93
Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol (2005) 2.51
Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther (2007) 2.38
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther (2008) 2.31
Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics (1992) 2.21
Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med (1990) 2.03
Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr (2003) 1.89
Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther (2008) 1.74
Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend (2008) 1.57
Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol (2001) 1.51
Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther (2009) 1.48
Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther (1997) 1.48
ACOG Committee Opinion No. 422: at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice. Obstet Gynecol (2008) 1.38
Trimester-specific reference intervals for thyroxine and triiodothyronine in pregnancy in iodine-sufficient women using isotope dilution tandem mass spectrometry and immunoassays. Clin Chim Acta (2004) 1.30
Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy. Br J Obstet Gynaecol (1981) 1.30
24-hour creatinine clearance during the third trimester of normal pregnancy. Br J Obstet Gynaecol (1980) 1.27
Tandem mass spectrometry improves the accuracy of free thyroxine measurements during pregnancy. Thyroid (2007) 1.25
Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry (2008) 1.22
Teratogenicity of SSRIs--serious concern or much ado about little? N Engl J Med (2007) 1.22
Estimation of uterine blood flow in normal human pregnancy at term. J Clin Invest (1955) 1.21
Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol (2003) 1.15
Transit time in the small intestine in pregnancy. J Obstet Gynaecol Br Commonw (1970) 1.13
Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol (2005) 1.05
Physiologic changes in pregnancy. Surg Clin North Am (2008) 1.05
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther (2005) 0.98
Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res (1990) 0.97
The kidney and hypertension in pregnancy: twenty exciting years. Semin Nephrol (2001) 0.95
The effect of pregnancy on kidney function in renal allograft recipients. Kidney Int (1985) 0.92
Physiologic changes in pregnancy and their impact on critical care. Crit Care Med (2005) 0.88
Apparent liver blood flow during pregnancy: a serial study using indocyanine green clearance. Br J Obstet Gynaecol (1990) 0.83
The effect of pregnancy on gastric secretion. N Engl J Med (1956) 0.83
Cardiorespiratory alterations during normal pregnancy. Crit Care Clin (1991) 0.78
Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy. Clin Transl Sci (2009) 0.77
New perspectives on the benefit-cost and cost-effectiveness of drug abuse treatment. NIDA Res Monogr (1991) 0.76
Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid (2011) 8.77
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Contemporary cesarean delivery practice in the United States. Am J Obstet Gynecol (2010) 5.00
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry (2005) 4.45
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA (2005) 3.74
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol (2009) 3.52
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry (2006) 3.01
Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J Pediatr (2011) 2.86
Assisted reproductive technology and pregnancy outcome. Obstet Gynecol (2005) 2.77
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol (2010) 2.62
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol (2008) 2.24
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
Symptoms of depressed mood, disturbed sleep, and sexual problems in midlife women: cross-sectional data from the Study of Women's Health Across the Nation. J Womens Health (Larchmt) (2015) 2.05
The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry (2009) 2.01
Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA (2004) 1.97
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat (2007) 1.92
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am J Psychiatry (2015) 1.89
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician (2007) 1.83
Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril (2007) 1.82
Accuracy of the diagnosis of physical features of fetal alcohol syndrome by pediatricians after specialized training. Pediatrics (2006) 1.80
Correlations of free thyroid hormones measured by tandem mass spectrometry and immunoassay with thyroid-stimulating hormone across 4 patient populations. Clin Chem (2009) 1.79
Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry (2013) 1.79
Isotope dilution tandem mass spectrometric method for T4/T3. Clin Chim Acta (2004) 1.77
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev (2012) 1.73
Simultaneous quantification of free triiodothyronine and free thyroxine by isotope dilution tandem mass spectrometry. Clin Biochem (2007) 1.68
Full breastfeeding and paediatric cancer. J Paediatr Child Health (2007) 1.65
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
More codeine fatalities after tonsillectomy in North American children. Pediatrics (2012) 1.63
Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry (2004) 1.62
Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res (2006) 1.61
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry (2008) 1.59
Probability of hysterectomy after endometrial ablation. Obstet Gynecol (2008) 1.59
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache (2002) 1.57
Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med (2009) 1.57
Bridging the gap: recruitment of African-American women into mental health research studies. Acad Psychiatry (2003) 1.57
Serotonin syndrome associated with triptan monotherapy. N Engl J Med (2008) 1.54
Maternal and neonatal outcomes by labor onset type and gestational age. Am J Obstet Gynecol (2010) 1.54
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. BMC Genomics (2008) 1.49
Accuracy of depression screening tools for identifying postpartum depression among urban mothers. Pediatrics (2010) 1.48
Independent influence of dietary protein on markers of kidney function and disease in obesity. Kidney Int (2010) 1.48
Steroid hormone analysis by tandem mass spectrometry. Clin Chem (2009) 1.47
Postpartum depression: a major public health problem. JAMA (2006) 1.46
Nutrition and depression: implications for improving mental health among childbearing-aged women. Biol Psychiatry (2005) 1.46
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Characteristics associated with severe perineal and cervical lacerations during vaginal delivery. Obstet Gynecol (2011) 1.45
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses. J Clin Psychiatry (2015) 1.45
Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause (2014) 1.44
Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause (2014) 1.44
The effect of secondhand smoke exposure on markers of elastin degradation. Chest (2011) 1.41
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
Three cases of lithium exposure and exclusive breastfeeding. Arch Womens Ment Health (2012) 1.41
A review of postpartum psychosis. J Womens Health (Larchmt) (2006) 1.40
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
Reduced methadone clearance during aromatase inhibition. J Clin Psychopharmacol (2012) 1.39
Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry (2010) 1.38
Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol (2011) 1.36
Beyond race or ethnicity and socioeconomic status: predictors of prenatal testing for Down syndrome. Obstet Gynecol (2006) 1.36
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer (2010) 1.34
Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry (2009) 1.34